
    
      This is a trial designed to assess the safety and tolerability of multiple-dose
      administrations of aripiprazole intramuscular (IM) depot in the deltoid muscle in adult
      subjects with schizophrenia. The trial consists of a 113 day treatment period with a 28 day
      followup. The trial population will include male and female subjects between 18 and 64 years
      (inclusive), with a current diagnosis of schizophrenia as defined by DSM-IV-TR criteria and a
      prior history of tolerating aripiprazole per investigator's judgement.
    
  